Restoring Regulatory T Cells in Type 1 Diabetes
- PMID: 27664043
- DOI: 10.1007/s11892-016-0807-6
Restoring Regulatory T Cells in Type 1 Diabetes
Abstract
Genetic and cellular studies of type 1 diabetes in patients and in the nonobese diabetic mouse model of type 1 diabetes point to an imbalance between effector T cells and regulatory T cells (Tregs) as a driver of the disease. The imbalance may arise as a consequence of genetically encoded defects in thymic deletion of islet antigen-specific T cells, induction of islet antigen-specific thymic Tregs, unfavorable tissue environment for peripheral Treg induction, and failure of islet antigen-specific Tregs to survive in the inflamed islets secondary to insufficient IL-2 signals. These understandings are the foundation for rationalized design of new therapeutic interventions to restore the balance by selectively targeting effector T cells and boosting Tregs.
Keywords: CTLA-4; IL-2; Nonobese diabetic (NOD) mice; Regulatory T cells (Tregs); Therapy; Type 1 diabetes.
Similar articles
-
Revealing the specificity of regulatory T cells in murine autoimmune diabetes.Proc Natl Acad Sci U S A. 2018 May 15;115(20):5265-5270. doi: 10.1073/pnas.1715590115. Epub 2018 Apr 30. Proc Natl Acad Sci U S A. 2018. PMID: 29712852 Free PMC article.
-
Combination Therapy Using IL-2/IL-2 Monoclonal Antibody Complexes, Rapamycin, and Islet Autoantigen Peptides Increases Regulatory T Cell Frequency and Protects against Spontaneous and Induced Type 1 Diabetes in Nonobese Diabetic Mice.J Immunol. 2015 Dec 1;195(11):5203-14. doi: 10.4049/jimmunol.1402540. Epub 2015 Oct 19. J Immunol. 2015. PMID: 26482409
-
ICOS-dependent homeostasis and function of Foxp3+ regulatory T cells in islets of nonobese diabetic mice.J Immunol. 2012 Feb 1;188(3):1064-74. doi: 10.4049/jimmunol.1101303. Epub 2012 Jan 6. J Immunol. 2012. PMID: 22227569
-
Interactions of effectors and regulators are decisive in the manifestations of type 1 diabetes in nonobese diabetic mice.Curr Dir Autoimmun. 2001;4:171-92. doi: 10.1159/000060537. Curr Dir Autoimmun. 2001. PMID: 11569402 Review. No abstract available.
-
Emerging Therapeutic Strategies to Restore Regulatory T Cell Control of Islet Autoimmunity in Type 1 Diabetes.Front Immunol. 2021 Mar 18;12:635767. doi: 10.3389/fimmu.2021.635767. eCollection 2021. Front Immunol. 2021. PMID: 33815387 Free PMC article. Review.
Cited by
-
The Effect of Immunosuppressive Adjuvant Kynurenine on Type 1 Diabetes Vaccine.Front Immunol. 2021 Jul 7;12:681328. doi: 10.3389/fimmu.2021.681328. eCollection 2021. Front Immunol. 2021. PMID: 34305913 Free PMC article.
-
Low-dose interleukin-2 as a modulator of Treg homeostasis after HSCT: current understanding and future perspectives.Int J Hematol. 2018 Feb;107(2):130-137. doi: 10.1007/s12185-017-2386-y. Epub 2017 Dec 12. Int J Hematol. 2018. PMID: 29234980 Review.
-
A Sensitive Method for Detecting Peptide-specific CD4+ T Cell Responses in Peripheral Blood from Patients with Myasthenia Gravis.Front Immunol. 2017 Oct 24;8:1370. doi: 10.3389/fimmu.2017.01370. eCollection 2017. Front Immunol. 2017. PMID: 29114250 Free PMC article.
-
Immune checkpoint inhibitors and type 1 diabetes mellitus: a case report and systematic review.Eur J Endocrinol. 2019 Sep;181(3):363-374. doi: 10.1530/EJE-19-0291. Eur J Endocrinol. 2019. PMID: 31330498 Free PMC article.
-
Management of endocrine immune-related adverse events of immune checkpoint inhibitors: an updated review.Endocr Connect. 2020 Oct;9(10):R207-R228. doi: 10.1530/EC-20-0342. Endocr Connect. 2020. PMID: 33064663 Free PMC article. Review.
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical